A Phase 2 interventional study of Caelyx in Ovarian Cancer, sponsored by North Eastern German Society of Gynaecological Oncology. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-16.
Sponsored by North Eastern German Society of Gynaecological Oncology · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing liposomal doxorubicin in Ovarian Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. liposomal doxorubicin · Ovarian Neoplasms.
Among the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms, this one is the 15th largest by enrollment, is the only one that started in 2001, is one of 14 in phase 2, and was the 2nd registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →None of the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →
liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 21 · Phase 3 9 · Phase 4 1
First in 1997; this study’s year is marked. 1 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is above the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 53 across the 42 interventional studies. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 42 have an industry lead sponsor. The 10 most frequent:
North Eastern German Society of Gynaecological Oncology is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
12 studies in Ovarian Neoplasms by North Eastern German Society of Gynaecological Oncology: 1 open now, 2 under way, none of them phase 3. Of 10 finished, 4 (40%) have results posted.
Among the 12 studies in Ovarian Neoplasms by North Eastern German Society of Gynaecological Oncology, this one is the 9th largest by enrollment, is the only one that started in 2001, is one of 6 in phase 2, and was the 1st registered.
North Eastern German Society of Gynaecological Oncology’s Ovarian Neoplasms studies by the year they started, since 1999.
1 of the studies testing liposomal doxorubicin in Ovarian Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01970722City of Hope Medical CenterSurgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | 2027-01-05 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms, from their registry updates:
Among North Eastern German Society of Gynaecological Oncology’s 12 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
Effect of biweekly schedule of PLD on dose-limiting toxicity of PPE and patient's quality of life
Pegylated liposomal doxorubicin (PLD) formulation has been approved for the treatment of recurrent ovarian cancer (ROC). Toxic skin reactions e.g. palmar-plantar erythrodysesthesia (PPE) were reported as being the dose-limiting toxicity and have an impact on patients' quality of life (QoL). The primary aim of this study was to optimise the toxicity profile by choosing a biweekly schedule of PLD Furthermore, QoL was investigated. Secondary objective of this study was to evaluate the response rates of this new regimen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 mg/m² biweekly
Drug: Caelyx
40 mg/m² biweekly
Occurrence of Palmar-plantar Erythrodysesthesia (PPE)
The outcome will be measured by number of participants with reported skin toxicity PPE of CTC (Common Toxicity Criteria)-Grade I / II / III / IV. Grade I - Dysesthesia/paraesthesia tingling of hands and feet; Grade II - Discomfort in holding objects and upon walking, painless swelling and erythema; Grade III - painful erythema and swelling of palms and soles, periungual erythema and swelling; Grade IV - Desquamation, ulceration, blistering, severe pain
Time frame: through study completion, an average of 18 months
Overall Survival
Overall survival estimated by the Kaplan-Meier method
Time frame: for up to 3 years
recruitment period: September 2001 - February 2004
| Milestone | Caelyx |
|---|---|
| Started | 77 |
| Completed | 64 |
| Not completed | 13 |
| Withdrew: Violation of inclusion criteria | 13 |
The outcome will be measured by number of participants with reported skin toxicity PPE of CTC (Common Toxicity Criteria)-Grade I / II / III / IV. Grade I - Dysesthesia/paraesthesia tingling of hands and feet; Grade II - Discomfort in holding objects and upon walking, painless swelling and erythema; Grade III - painful erythema and swelling of palms and soles, periungual erythema and swelling; Grade IV - Desquamation, ulceration, blistering, severe pain
| Participants | Caelyx |
|---|---|
| CTC-Grade I | 18 |
| CTC-Grade II | 9 |
| CTC-Grade III | 3 |
| CTC-Grade IV | 0 |
| no PPE | 34 |
Overall survival estimated by the Kaplan-Meier method
| months | Caelyx |
|---|---|
| Overall Survival | 18.2 (1.4 to 34.0) |
Collected over through study completion, an average of 18 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Caelyx | — | 4/64 (6.3%) | 60/64 (93.8%) |
| Event | Caelyx |
|---|---|
| AnemiaBlood and lymphatic system disorders | 3/64 |
| ThrombopeniaBlood and lymphatic system disorders | 1/64 |
| Event | Caelyx |
|---|---|
| PPESkin and subcutaneous tissue disorders | 30/64 |
| LeucopeniaBlood and lymphatic system disorders | 26/64 |
| ThrombopeniaBlood and lymphatic system disorders | 4/64 |
| Age, Continuous(years) | Caelyx |
|---|---|
| Median | 59 (38 to 81) |
| Sex: Female, Male(Participants) | Caelyx |
|---|---|
| Female | 64 |
| Male | 0 |
| Region of Enrollment(participants) | Caelyx |
|---|---|
| Germany | 64 |
| Classification of tumour (according to FIGO ovarian cancer staging)(participants) | Caelyx |
|---|---|
| stage IA | 2 |
| stage IB | 0 |
| stage IC | 1 |
| stage IIA | 8 |
| stage IIB | 2 |
| stage IIC | 4 |
| stage IIIA | 2 |
| stage IIIB | 3 |
| stage IIIC | 34 |
| stage IV | 7 |
| unknown | 1 |
| Histological grade(participants) | Caelyx |
|---|---|
| grade 1 | 8 |
| grade 2 | 20 |
| grade 3 | 28 |
| grade 4 | 0 |
| unknown | 8 |
| ECOG performance status(participants) | Caelyx |
|---|---|
| 0 | 20 |
| 1 | 34 |
| 2 | 10 |
| 3 | 0 |
| 4 | 0 |
| 5 | 0 |
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Sep 2001, a primary completion of Apr 2009 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2024, 15 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal doxorubicin
North Eastern German Society of Gynaecological Oncology